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Introduction: The oxidoreductase WWOX was initially described
as a putative tumor suppressor in breast cancer. Non-small cell lung
cancers (NSCLCs) frequently show aberrant WWOX expression.
Herein, we characterized WWOX at a functional level in preclinical
NSCLC models and in primary NSCLC biopsies.
Methods: The human wild-type (wt) WWOX complementary DNA
and a mutant WWOXA132T with structurally disrupted short-chain
dehydrogenase/reductase domain were conditionally expressed at
physiological levels in several human NSCLC models. Resulting
transgenic cell populations were analyzed with respect to clonogenic
survival and apoptosis sensitivity in vitro and tumor growth in
immune-deficient mice. Tissue microarrays prepared from surgically
resected primary human NSCLC tumors were studied to correlate
intratumoral WWOX expression with patient outcomes.
Results: Conditional expression of wt WWOX, but not mutant
WWOXA132T, suppressed clonogenic survival of NSCLC cells in
vitro and tumor growth in vivo. In addition, preserved intratumoral
WWOX expression was associated with improved outcome in a
cohort of 85 patients with surgically resected NSCLC. Unexpect-
edly, wt WWOX failed to sensitize NSCLC cells to various apopto-
tic stimuli but robustly protected against apoptosis induced by
inhibitors of growth factor signal transduction.
Conclusions:WWOX acts as a tumor suppressor in human NSCLC
models in a short-chain dehydrogenase/reductase domain-dependent
manner. This activity is independent of sensitization to apoptotic cell
death. WWOX expression as detected by immunohistochemistry may
be a prognostic biomarker in surgically resected, early-stage NSCLC.
Key Words: WWOX, Non-small cell lung cancer, Apoptosis,
Biomarker.
(J Thorac Oncol. 2011;6: 1976–1983)
Non-small cell lung cancers (NSCLCs) are the leadingcause of cancer mortality in the Western World. Al-
though inhalative cigarette smoking has been established as
the dominant risk factor for the development of NSCLC, the
complete oncogenic process is less well characterized and
certainly differs between various histologically and geneti-
cally defined NSCLC subsets. Recently, the concept of “ge-
netic dependence” to specific oncogenic “driver mutations”
has drawn much attention in lung cancer pathophysiology
research. It has been paradigmatically demonstrated in pul-
monary adenocarcinomas bearing activating mutations and
amplification of the epidermal growth factor receptor or
translocations of the anaplastic lymphoma kinase (ALK),
both aberrations clustering in patients without smoking his-
tory.1–5 Functional dependence to gene amplification involv-
ing the fibroblast growth factor receptor 1 has been observed
in a subgroup of pulmonary squamous cell carcinomas, thus
extending the concept to smoking-associated NSCLC.6 In
addition to such “druggable” oncogenic driver lesions, func-
tional inactivation of tumor suppressor gene products is
regarded an important step in lung carcinogenesis. Moreover,
this is thought to contribute to resistance of NSCLC to
DNA-damaging agents and radiation, which are still the
mainstay of nonsurgical lung cancer treatment. A key exam-
ple are inactivating mutations of the TP53 tumor suppressor,
which are found in approximately 50% of NSCLC, and which
may result in functional impairment of the treatment-induced
DNA damage response.7,8
Next to the TP53 gene product, additional tumor sup-
pressors have been implied in lung cancer pathophysiology.
The putative tumor suppressor gene WW domain-containing
oxidoreductase (WWOX) localizes at the common fragile site
FRA16D on chromosome 16q, which is frequently affected
by structural genetic aberrations in cancer.9 WWOX was
originally described in breast cancer,10 but loss of heterozy-
gosity was observed in 37% of lung cancers, and expression
of aberrant WWOX transcripts was found in 25% of lung
cancers studied.11 Immunohistochemical studies detected re-
duced or absent WWOX protein expression in 85% of cases,
with highest rates in squamous cell carcinomas and undiffer-
entiated carcinoma.12 Next to expression of aberrant tran-
scripts, epigenetic inactivation by WWOX promoter hyper-
methylation and mutations of the short-chain dehydrogenase/
reductase (SDR) domain have been reported in primary lung
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cancers.13 Gene targeting of Wwox in the mouse resulted in
increased formation of juvenile osteosarcomas in homozy-
gously deleted mice and papillary lung tumors in heterozy-
gously deleted mice. Importantly, the latter exhibited en-
hanced carcinogen-induced lung tumorigenesis, supporting a
role for WWOX as a lung cancer tumor suppressor.14 This
was further bolstered by the induction of apoptosis following
heterologous overexpression ofWWOX complementary DNA
(cDNA) in human lung cancer models.15
Against this background, we have developed models of
conditional expression of wild-type (wt) WWOX and a SDR
domain-mutant WWOX cDNA at physiological levels in
NSCLC. Although we confirm a tumor-suppressive activity
of WWOX in vitro and in vivo, which depends on a struc-
turally intact SDR domain, we fail to demonstrate proapop-
totic activity of the transgene. Surprisingly, WWOX protects
lung cancer cells against apoptosis induced by broad-spec-
trum kinase inhibitors. Studying WWOX protein expression
in a series of surgically resected NSCLC reveals that low
intratumoral WWOX staining correlates with dismal out-
come. These findings support a role for WWOX as lung
cancer tumor suppressor, which, however, is not explained by
enhancing apoptotic cell death.
MATERIALS AND METHODS
Reagents
Etoposide, paclitaxel, and staurosporine were purchased
from Sigma-Aldrich (Munich, Germany). KN-93 (Ca/Calmod-
ulin-dependent-kinase II inhibitor) was obtained from Alexis
Biochemicals (Switzerland). Wortmannin (PI3-kinase inhibitor),
genistein (general tyrosine kinase inhibitor), U0126 (MEK in-
hibitor), Akt-inhibitor VIII, and BAPTA-AM (cell permeable
Ca2 chelator) were purchased from Calbiochem (Schwalbach,
Germany). 17AAG (heat shock protein 90 inhibitor) was ob-
tained from LC Laboratories (Woburn, MA). protein kinase C
(PKC) 412 (PKC inhibitor) was provided by Novartis (Basel,
Switzerland), and ABT-737 was provided by Abbott (Abbott
Park, IL).
Cell Lines and DNA Constructs
NSCLC cell lines A549, NCl-H460 and NCl-H1299,
and the breast cancer cell line, MCF-7, were maintained in
Dulbecco’s Modified Eagle Medium media supplemented
with 10% fetal calf serum (FCS, Invitrogen, San Diego, CA).
wt human WWOX cDNA fused to a FLAG tag-encoding
sequence at its 3 end and a mutant WWOX cDNA resulting
in an amino acid exchange at codon 132 (WWOXA132T) were
cloned into pRevTRE (Clontech Laboratories, Mountain View,
CA). A549, NCI-H460, and NCI-H1299 cells stably expressing
a mutant rtTA-M2 transactivator16 were retrovirally transduced
with pRevTRE_WWOX-FLAG or pRevTRE_WWOXA132T-
FLAG and were selected with hygromycin.
Antibodies for Immunoblotting and
Immunohistochemistry
To prepare protein extracts, cells were washed with
ice-cold phosphate-buffered saline and lysed in NP40-con-
tainig lysis buffer, supplemented with protease and phospha-
tase inhibitors. Protein expression and phosphorylation were
analyzed by immunoblotting. The following WWOX anti-
bodies were used: Ab-1 from Oncogene (San Diego, CA;
rabbit polyclonal, N1, cat.No. AP1007, epitope AA 89-107),
Ab-2 from Everest Biotech (Oxfordshire, UK; goat poly-
clonal, cat. No EB07053, epitope AA 38-51), and Ab-3 from
Abcam (Cambridge, UK; rabbit polyclonal, cat. No ab14691,
epitope AA 397-411). Antibodies against phospho-Akt
(Ser473), phospho-S6 ribosomal protein (Ser240/244), phos-
pho-glykogen synthase kinase-3 (Ser9), and phospho-
Erk1/2 (Thr202/Tyr204) were purchased from Cell Signaling
Technology (Frankfurt, Germany). Antiphosphotyrosine
(4G10) antibody was from Upstate (Lake Placid, USA),
antitubulin and anti-FLAG antibodies were from Sigma-
Aldrich (Munich, Germany), and antiactin antibody was from
MP Biomedicals (Aurora, OH). Immunohistochemical stain-
ings were performed as described previously17 using WWOX
Ab-3 as primary antibody.
Apoptosis Assays
The percentage of apoptotic cells was determined by
flow cytometric measurement of the fraction of cells with
subgenomic DNA content on propidium iodide staining of
permeabilized cells. For some studies, apoptosis was further
confirmed by parallel experiments using the FITC Annexin V
Apoptosis Detection Kit II (BD Biosciences, Germany).
Colony Assays
To determine clonogenic survival, 5000 cells/well (six-
well plate) were seeded in the presence or absence of doxy-
cycline (1 g/ml) and were cultured for 5 to 7 days. Colonies
were fixed with 70% ethanol and stained with Coomassie
Brilliant Blue for visualization. To study anchorage-indepen-
dent colony formation, 1500 cells/well (24-well plate) were
seeded and cultured in 0.35% soft agar, which was dissolved
in Dulbecco’s Modified Eagle Medium supplemented with
10% FCS either in presence or absence of doxycycline
(1 g/ml) for 7 to 14 days. Colonies were stained with 3-(4,5-
dimethyl-thiazoyl-2-yl)-2,5-diphenyltetrazolium bromide (0.5
mg/ml) for 2 hours at 37°C for photomicrographic documenta-
tion and enumeration.
Murine Tumor Model
Irradiated (150 rad) nonobese diabetic/severe combined
immunodeficient (NOD/SCID) mice received subcutaneous
flank injections of 107 A549-WWOX-FLAG or A549-
WWOXA132T-FLAG cells. For induction of conditional
WWOX expression in vivo, the drinking water was supple-
mented with doxycycline (1 mg/ml). Tumor growth was moni-
tored by bidimensional measurements using a caliper. All ani-
mal studies were conducted in compliance with institutional
guidelines and German Animal Protection Law.
Tissue Microarray Analyses
Demographic and clinical characteristics of the study
population are summarized in Supplemental Table 1 (http://
links.lww.com/JTO/A130). The construction of the tissue
microarrays (TMA), immunohistochemical, and statistical
analyses have been described previously.17 In brief, TMA
sections were immunohistochemically analyzed using the
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WWOX Ab-3 (Abcam, Cambridge, UK; rabbit polyclonal,
cat. No ab14691, epitope AA 397-411) as primary antibody.
Specific immunoreactivity was quantified by an immunore-
activity score (IRS),18–20 which is based on the product of
staining intensity (0  absent, 1–3  weak, moderate, high)
and fraction of positively staining tumor cells (0  absent,
1  1–9%, 2  10–50%, 3  51–80%, and 4  80%).
Hence, resulting IRS values range from 0 to 12.
Statistical Methods
Results obtained in cell biology experiments were an-
alyzed using the GraphPad Prism 4 software (Student’s t
test). Data from mouse experiments (analysis of variance)
and survival data of patients with lung cancer (Mantel-Cox
Log-rank test) were statistically analyzed by means of the
SPSS software, version 18.
RESULTS
Tumor-Suppressive Activity of WWOX Requires
a Structurally Intact SDR Domain
To study the functional consequences of WWOX ex-
pression in NSCLC cells, we devised a retroviral vector
system equipped with a tetracycline-inducible promoter. We
generated several constructs expressing the human WWOX
cDNA and a WWOX cDNA fused to a FLAG tag-encoding
sequence at its 3 end. Similar vectors were designed encod-
ing a mutant WWOX with an amino acid exchange at codon
132 (WWOXA132T), which was generated by random mu-
tagenesis. The selection of this mutant for further study was
based on biochemical considerations, which predicted a struc-
turally altered SDR domain due to replacement of alanine at
position 132 by differently charged and sized threonine. These
constructs were used to transduce A549, NCI-H460, and NCI-
H1299 NSCLC cells stably expressing a mutant rtTA-M2 trans-
activator,16 thus enabling conditional transgene expression on
treatment with doxycycline. The resulting cellular systems al-
lowed the validation of several antibodies, which had been
reported to specifically detect endogenously expressed WWOX.
Cell extracts were prepared from MCF-7 breast cancer cells,
which express wt WWOX,10 and were subjected to immu-
noblotting. All three tested antibodies detected a band of
the expected molecular mass of approximately 44 kDa.
Surprisingly, only one of these antibodies (further denoted
Ab-3) crossreacted with the conditionally expressed
WWOX-FLAG fusion protein, which was readily detected
using an anti-FLAG monoclonal antibody (Supplemental
Figure 1, http://links.lww.com/JTO/A131). This antibody
was used for all further experimentation.
Conditional expression of wt WWOX reproducibly
imposed a moderate inhibition of clonogenic survival and
anchorage-independent colony formation of A549, NCI-
H460, and NCI-H1299 cells in vitro (Figure 1, Supplemental
Figure 2, http://links.lww.com/JTO/A132). Interestingly, no
suppression of clonogenic survival was observed on expres-
sion of the WWOXA132T mutant bearing a structurally dis-
rupted SDR domain (Figure 1). This suggested that a struc-
turally and possibly functionally preserved SDR domain is
required for the tumor-suppressive activity of WWOX in
NSCLC models. To further substantiate this hypothesis, we
grafted A549 cells conditionally expressing WWOX (A549-
WWOX) or WWOXA132T (A549-WWOXA132T) in immune-
deficient NOD/SCID mice and monitored tumor growth.
Feeding doxycycline to NOD/SCID mice grafted with A549-
WWOX cells to induce intratumoral expression of wt
WWOX significantly (p  0.006, analysis of variance) sup-
pressed the growth of NSCLC tumors in vivo, when com-
pared with tumor growth in mice not fed with doxycycline
(Figure 2A). In contrast, induction of WWOXA132T in vivo
failed to suppress the growth of A549-WWOXA132T xeno-
grafts, when compared with mice not receiving doxycycline
(Figure 2B). Transgene expression in response to doxycycline
treatment was confirmed by immunohistochemical analysis
of explanted A549-WWOX tumors (Figure 2C). Hence,
WWOX acts as a tumor suppressor in NSCLC models in vitro
and in vivo, and this activity depends on a structurally intact
SDR domain.
WWOX Expression is Associated with an
Improved Outcome in Patients with
Early-Stage NSCLC
To explore WWOX as a modulator of NSCLC biology
in patients, we studied TMA prepared from 85 NSCLC
FIGURE 1. WWOX inhibits clonogenic survival of non-small
cell lung cancer (NSCLC) cells in vitro. A549, NCI-H460, and
H1299 cells, transduced with wt-WWOX or WWOXA132T
mutant, were seeded in six-well plates. WWOX expression
was induced by addition of doxycycline (Dox) in the cul-
ture medium. Developing colonies were stained after 5 to 7
days incubation. Representative photomicrographs of at least
three independent experiments.
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tumors obtained at surgical resection (Supplemental Table
1).17 An established IRS ranging from 0 to 1218 was applied
to classify tumors (Figure 3A) as WWOX negative (IRS 3),
WWOX positive (IRS 3), or strongly positive (IRS 8).
Patients with preserved intratumoral WWOX expression
(IRS 3) had a significantly (p  0.022, Log rank Mantel-
Cox test) superior outcome after surgical resection, when
compared with patients suffering from NSCLC, which
stained negatively for WWOX (Figure 3B). No significant
association between WWOX expression and established
prognostic parameters, such as tumor stage, age, and gender,
was observed (data not shown). These findings lend further
support to a role for WWOX as tumor suppressor in lung
cancer.
WWOX Protects Lung Cancer Cells against
Apoptosis Induced by Broad Spectrum Kinase
Inhibitors
Overexpression of WWOX has been reported to induce
apoptotic cell death in lung cancer models.15 Accordingly, a
proapoptotic activity is viewed as the mechanistic basis for
WWOX-imposed tumor suppression. Against this back-
ground, we devised our systems to further study the proapo-
ptotic activity of conditionally expressed WWOX in NSCLC
models. Induction of both, WWOX and WWOXA132T at
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FIGURE 3. WWOX expression is associated with an im-
proved outcome in patients with surgically treated non-small
cell lung cancer (NSCLC) cancer. A, Representative photomi-
crographs of immunohistochemical stainings of NSCLC with
absent (IRS  0), weak (actual immunoreactivity score [IRS]
in brackets), moderate, and strong endogenous WWOX ex-
pression. B, Kaplan-Meier Plot of overall survival of a cohort
of 85 patients with surgically resected NSCLC in relationship
to WWOX expression status. Patients with WWOX-positive
tumors (yellow line) showed a significantly improved survival
(p  0.022, Log rank [Mantel Cox] test), when compared
with patients with WWOX-negative tumors (blue line).
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FIGURE 2. Inhibition of tumor growth by WWOX in a mu-
rine xenograft model. Growth of A549-WWOX (A) and
A549-WWOXA132T (B) xenografts in nonobese diabetic/
severe combined immunodeficient (NOD/SCID) mice treated
with doxycycline (Dox, closed triangles) or vehicle
(Dox, open boxes). C, Immunohistochemical analysis of
transgene expression in response to doxycycline treatment
from explanted A549-WWOX tumors. IRS, immunoreactivity
score; 12  strongly positive.
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physiological expression levels (Supplemental Figure 1C)
failed to trigger apoptosis of NSCLC cells in vitro or in vivo
(not shown). Next, we assessed whether conditional restora-
tion of WWOX in NSCLC cells impacts on apoptosis induced
by various exogenous stimuli. To exclude potential artifacts
resulting from cotreatment with doxycycline, NSCLC cell
lines stably expressing the rtTA-M2 transactivator, but not
the WWOX expression vectors, were used as controls. Con-
ditional expression of WWOX failed to modulate cell death
in response to etoposide, paclitaxel, or UV radiation in A549
and NCI-H460 NSCLC cells (Figures 4C, D and not shown).
Surprisingly, NSCLC cells expressing WWOX were signifi-
cantly protected against apoptosis induced by the broad
spectrum kinase inhibitor staurosporine (Figure 4A, Supple-
mental Figures 3A, B, http://links.lww.com/JTO/A133). This
finding was in stark contrast to the proapoptotic activity of
WWOX overexpression in lung cancer and additional cancer
models.15,21–23 As all these stimuli are able to trigger several
cell death mechanisms in addition to apoptosis, we next
devised ABT-737, a pharmacologic BH3 mimetic with a
purely proapoptotic mechanism of action in lung cancer
models.24,25 In line with our previous findings, conditionally
expressed WWOX had no impact on apoptosis induced by
ABT-737 treatment of A549 and NCI-H460 cells in vitro
(Figure 4E).
Next, we studied whether the protective activity of
WWOX was restricted to staurosporine-induced apoptosis or
represented a more general phenomenon. To this end,
NSCLC cells were treated with a panel of pharmacologic
compounds inhibiting various protein kinases, such as PI3K
(wortmannin), PKC412, Akt (Akt-inhibitor VIII), MEK
(U0126), the kinase chaperone heat shock protein 90
(17AAG), or calcium-dependent intracellular signaling
(BAPTA-AM, KN93). Although WWOX failed to modulate
cell death induced by the latter compounds, it consistently
protected cells against apoptosis induced by the general
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FIGURE 4. WWOX protects lung cancer cells against apoptosis induced by staurosporine and genistein. A, A549-WWOX cells
(left), NCl-H460-WWOX cells (center), and NCI-H1299-WWOX cells (right) were treated for 48 hours with indicated concen-
trations of staurosporine in WWOX-induced (Dox) or -uninduced (Dox) state. Cells were permeabilized and stained with
propidium iodide, and the percentage of cells with sub-G1 DNA content, corresponding to apoptotic cells, was determined
by flow cytometry. B, A549-WWOX cells (left), NCl-H460-WWOX cells (center), and NCI-H1299-WWOX cells (right) were
treated for 48 hours with indicated concentrations of genistein in WWOX-induced (Dox) or -uninduced (Dox) state. The
fraction of apoptotic cells was determined as in (A). A549-WWOX and NCl-H460-WWOX cells in WWOX-induced (Dox)
or -uninduced (Dox) state were treated for 48 hours with etoposide (12.5 M, C) or UV-C irradiation (20 mJ/cm2, D).
Apoptosis was determined as in (A). E, Apoptosis induction in A549-WWOX cells on 48 hours treatment with 25 or 50
M of ABT-737 in WWOX-induced (Dox) or -uninduced (Dox) state. Mean values  standard deviation from three
independent experiments; ***p  0.0002; **p  0.0086; *p  0.0374 (unpaired t test).
Becker et al. Journal of Thoracic Oncology • Volume 6, Number 12, December 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1980
FIGURE 5. Modulation of cell signaling by the kinase inhibitors staurosporine and genistein. A, A549-rtTA (control cells) and
A549-WWOX cells (upper panel) and NCI-H460-WWOX cells (lower panel) cultured in the presence () or absence of doxycy-
cline (Dox) were left untreated or were incubated for 4 hours with 250 M staurosporine or 100 M genistein. Cellular ly-
sates were analyzed by immunoblotting using the indicated primary antibodies. B, A549-rtTA (control cells) and A549-WWOX
cells were starved over night in Dulbecco’s Modified Eagle Medium containing 0.5% fetal calf serum (FCS). This was followed
by stimulation with Dulbecco’s Modified Eagle Medium containing 10% FCS and sequential (20 minutes) or simultaneous (4
hours) incubation with genistein (Gen, STS, 250 M, lower panel) as indicated.
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tyrosine kinase inhibitor genistein (Figure 4B, Supplemental
Figures 3B, C). We then assessed clonogenic survival of
NSCLC cells treated with staurosporine in relationship to
conditional expression of WWOX. This assay is influenced
by the antiproliferative activity of transgenic WWOX expres-
sion (Figure 1). Hence, results obtained for clonogenic long-
term survival are confounded, when compared with short-
term cell death assays, which are not influenced by cell
proliferation. Nevertheless, we found in NCI-H460 cells that
even clonogenic survival after staurosporine treatment can be
enhanced by conditional expression of the putative tumor
suppressor WWOX (Supplemental Figure 3D).
To further elucidate the mechanistic basis of this protec-
tion, we explored whether WWOX modulated the phosphory-
lation of protein kinase targets in the presence of staurosporine
or genistein. Immunoblot analyses of cell lysates prepared from
A549-WWOX cells, NCI-H460-WWOX cells, and the respec-
tive rtTA-M2 control cells revealed that staurosporine and
genistein effectively altered constitutive and serum-induced
phosphorylation of extracellular-signal regulated kinase, S6,
protein kinase B, or glykogen synthase kinase-3. Although
conditional expression of transgenic WWOX was preserved
under these experimental conditions, it failed to significantly
modulate the phosphorylation profile of these protein kinase
targets (Figures 5A, B). Probing the cell lysates with an antibody
reactive with phosphorylated tyrosines, pattern changes ob-
served in response to staurosporine and genistein treatment were
not consistently altered by expression of WWOX, thus arguing
against a modulation of the kinase inhibitory activity of these
agents by the transgene (Figure 5A).
DISCUSSION
Although a tumor-suppressive activity of WWOX was
corroborated by experiments conducted in several cancer
models and by gene targeted mice,14 the underlying molecu-
lar mechanism of action still is incompletely defined. Trans-
genic expression of WWOX at supraphysiological levels was
shown to induce apoptosis on its own or to sensitize cancer
cell lines to drug-induced cell death.26–28 These results have
to be interpreted with caution, as such type of studies might
overestimate the actual physiological role of a transgene
within the respective signal transduction pathway. Moreover,
mutation of the endogenous Drosophila homolog of WWOX
in vivo to study its role within a nonmammalian, physiolog-
ical context resulted in an unexpected outcome. Deficiency in
Drosophila WWOX resulted in enhanced sensitivity to radia-
tion-induced apoptosis, which was reduced by reintroduction
of either the human or Drosophila WWOX gene.29 Using
conditional expression at physiological levels (Supplemental
Figure 1C) in several human NSCLC cells with known
alterations of endogenous WWOX, we confirmed that wt
WWOX consistently suppressed tumor growth in vitro and in
vivo. In contrast, a WWOX mutant bearing a charge-relevant
amino acid exchange within the SDR domain failed to sup-
press tumor growth. This suggested that the tumor-suppres-
sive activity of WWOX depends on the SDR domain’s
structural integrity. Neither in vitro nor in vivo, we could
observe significant induction of apoptosis in response to
conditional WWOX expression. To the contrary, we unex-
pectedly found that WWOX protected NSCLC cells to apo-
ptosis induced by the broad-spectrum kinase inhibitors stau-
rosporine and genistein. By comprehensive analyses of
multiple protein kinase targets, we ruled out that this specific
protection resulted from interference with the inhibitory ac-
tivity of these agents or that these agents interfered with
conditional WWOX expression. Although at this point the
molecular basis of the protection by WWOX against specific
apoptotic stimuli remains unclear, it is tempting to speculate
that our findings may have revealed a second function of
WWOX in human cancer cells, which is distinct from its role
as a tumor suppressor. The latter is supported by the strictly
antiproliferative activity of WWOX in our experimental mod-
els in vitro and in vivo, which depended on a structurally
intact SDR domain. In contrast, WWOX protected against
apoptosis induced by kinase inhibitors.
In conclusion, our models of conditional expression of
WWOX at physiological levels support its role as a suppressor
of tumor growth in lung cancer in vitro and in vivo. This is in
keeping with the unfavorable outcome after surgical resection of
NSCLC observed in those patients with tumors staining nega-
tively for endogenousWWOX expression at immunohistochem-
istry. Nevertheless, from our data, it seems less likely that
WWOX exerts its tumor-suppressive activity by creating a
cellular context more permissive for stress-induced apoptosis.
To the contrary,WWOX protected NSCLC cells against specific
apoptotic stimuli as provided by broad-spectrum kinase inhibi-
tors. This unexpected finding is reminiscent of the result of
mutagenic inactivation of the Drosophila WWOX homolog in
vivo, which discovered a protective role of WWOX against
radiation-induced apoptosis.29 These observations point at a
second activity ofWWOX, which might be independent from its
role as a tumor suppressor.
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